Details for Patent: 10,059,714
✉ Email this page to a colleague
Which drugs does patent 10,059,714 protect, and when does it expire?
Patent 10,059,714 protects TRUQAP and is included in one NDA.
This patent has fifty-five patent family members in forty-four countries.
Summary for Patent: 10,059,714
| Title: | Protein kinase B inhibitors |
| Abstract: | The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I). |
| Inventor(s): | Paul David Johnson, Andrew Leach, Richard William Arthur Luke, Zbigniew Stanley Matusiak, Jeffrey James Morris |
| Assignee: | AstraZeneca AB |
| Application Number: | US15/351,481 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,059,714 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 10,059,714
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca | TRUQAP | capivasertib | TABLET;ORAL | 218197-001 | Nov 16, 2023 | RX | Yes | No | 10,059,714 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Astrazeneca | TRUQAP | capivasertib | TABLET;ORAL | 218197-002 | Nov 16, 2023 | RX | Yes | Yes | 10,059,714 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,059,714
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2201012 | ⤷ Start Trial | C02201012/01 | Switzerland | ⤷ Start Trial |
| European Patent Office | 2201012 | ⤷ Start Trial | 301299 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2201012 | ⤷ Start Trial | PA2024532 | Lithuania | ⤷ Start Trial |
| European Patent Office | 2201012 | ⤷ Start Trial | CA 2024 00047 | Denmark | ⤷ Start Trial |
| European Patent Office | 2201012 | ⤷ Start Trial | 2024C/543 | Belgium | ⤷ Start Trial |
| European Patent Office | 2201012 | ⤷ Start Trial | CR 2024 00047 | Denmark | ⤷ Start Trial |
| European Patent Office | 2201012 | ⤷ Start Trial | 122024000062 | Germany | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
